Twisting waves increase the visibility of nonlinear behaviour

Nonlinear behaviour for acoustic systems is readily measured at high acoustic pressures in gasses or bulk materials. However, at low acoustic pressures non-linear effects are not commonly observed. We find that by phase structuring acoustics beams, one observes evidence of non-linear behaviour at an acoustic pressure of 66.78 dB lower than non-structured beams in room temperature air. A bespoke 28-element ultrasonic phased array antenna was developed to generate short pulses that carry orbital angular momentum and are propagated over a short air channel. When sampling small areas of the wavefront, we observed a distinctive change in the frequency components near phase singularities. At these phase singularities the local propagation path is screwed, resulting in the collection signals from pulses traveling along different paths across the aperture of a microphone. The usually negligible frequency chirping that arises from nonlinear behaviour in air interfere at these singularity points and produce a distinctive distortion of the acoustic pulse. Simple physical movement in the system or super-sonic wave speeds do not yield similar results. Such distortions in measured frequency response near phase singularities could lead to errors for SONAR or acoustic communication systems, where received signals are integrated over a finite-area detector. With further development this behaviour could potentially lead to accurate measurement techniques for determining a material's nonlinear properties at lower acoustic pressure

Thin Film PZT-based PMUT Arrays for Microultrasound Capsule Endoscopy

Gastrointestinal (GI) disease is one of the most common causes of death. Capsule endoscopy (CE) may contribute to early detection of disease and pathological classification. Current CE relies on optical images of the internal luminal surface of the GI tract to aid diagnosis. With the addition of microultrasound, the imaging capability can be extended within the wall of the GI tract, with the potential to improve detection and classification. However, many challenges in fabrication and integration remain in the development of microultrasound transducer arrays to match CE geometry

Artropolis 93 : Public Art and Art About Public Issues

Contains 12 texts and documents works by nearly 300 Canadian artists in a Vancouver-based public art project. Includes artist's statements. 7 bibl. ref

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo